AUTHOR=Shi Yujiao , Dong Guoju , Liu Jiangang , Shuang Xiong , Liu Chunqiu , Yang Chenguang , Qing Wang , Qiao Wenbo 

TITLE=Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=9

YEAR=2022

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.854501

DOI=10.3389/fcvm.2022.854501

ISSN=2297-055X

ABSTRACT=<sec><title>Background</title><p>Heart failure with preserved ejection fraction (HFpEF) is an increasing public health concern. Currently, data regarding the clinical application value of plasma Galectin-3 (Gal-3) in HFpEF are contradictory. Therefore, we performed the following meta-analysis to appraise the clinical implications of serum Gal-3 in HFpEF, including its capacity to predict new-onset disease, long-term unfavorable endpoints, and the degree of cardiac structural abnormality and left ventricular diastolic dysfunction (LVDD).</p></sec><sec><title>Methods</title><p>PubMed, Embase, Scopus, and Web of Science were retrieved exhaustively from their inception until November 30, 2021, to obtain studies assessing the correlation between plasma Gal-3 and the clinical features of HFpEF (new-onset HFpEF, adverse outcomes, and echocardiographic parameters related to abnormal cardiac structure and LVDD).</p></sec><sec><title>Results</title><p>A total of 24 papers containing 27 studies were ultimately included in the present research. The results of the meta-analysis revealed that high plasma Gal-3 levels are strongly associated with the following clinical characteristics of HFpEF: (i) the increased risk of new-onset HFpEF (HR: 1.11; 95% CI: 1.04-1.19; <italic>p</italic> = 0.910, I<sup>2</sup> = 0%; <italic>P</italic> = 0.002); (ii) the high risk of adverse outcomes of HFpEF patients [all-cause death (HR: 1.55; 95% CI: 1.27-1.87; <italic>p</italic> = 0.138, I<sup>2</sup> = 42%; <italic>P</italic> = 0.000) and the composite events [all-cause death and HF hospitalization (HR: 1.50; 95% CI: 1.30-1.74; <italic>p</italic> = 0.001, I<sup>2</sup> = 61%; <italic>P</italic> = 0.000) or cardiovascular (CV) death and HF hospitalization (HR: 1.71; 95% CI: 1.51-1.94; <italic>p</italic> = 0.036, I<sup>2</sup> = 58%; <italic>P</italic> = 0.000)]; (iii) echocardiographic indices [E/e ratio (r: 0.425, 95% CI: 0.184-0.617; <italic>p</italic> = 0.000, I<sup>2</sup> = 93%; <italic>P</italic> = 0.001) and DT (r: 0.502, 95% CI: 0.061-0.779; <italic>p</italic> = 0.001 I<sup>2</sup> = 91%; <italic>P</italic> = 0.027)].</p></sec><sec><title>Conclusions</title><p>Plasma Gal-3 might be employed as an additional predictor for new-onset HFpEF, the adverse prognosis in HFpEF patients (all-cause death, the composite endpoints of all-cause death and HF hospitalization or CV death and HF hospitalization), and the severity of LVDD in HFpEF populations.</p></sec>